| Autor: |
Donders G; Femicare, Clinical Research for Women, Gasthuismolenstraat 31, 3300, Tienen, Belgium. Gilbert.Donders@Femicare.net.; Department of Gynaecology and Obstetrics, University Hospital of Antwerp, Antwerp, Belgium. Gilbert.Donders@Femicare.net., Bellen G; Femicare, Clinical Research for Women, Gasthuismolenstraat 31, 3300, Tienen, Belgium., Oerlemans E; Department of Bioscience Engineering, Research group Environmental Ecology and Microbiology, University of Antwerp, Antwerp, Belgium., Claes I; Department of Bioscience Engineering, Research group Environmental Ecology and Microbiology, University of Antwerp, Antwerp, Belgium.; YUN NV, Aartselaar, Belgium., Ruban K; Femicare, Clinical Research for Women, Gasthuismolenstraat 31, 3300, Tienen, Belgium., Henkens T; Department of Pharmaceutical, Biomedical and Veterinary Sciences, Laboratory of Pharmaceutical Technology and Biopharmacy, University of Antwerp, Antwerp, Belgium., Kiekens F; Department of Pharmaceutical, Biomedical and Veterinary Sciences, Laboratory of Pharmaceutical Technology and Biopharmacy, University of Antwerp, Antwerp, Belgium., Lebeer S; Department of Bioscience Engineering, Research group Environmental Ecology and Microbiology, University of Antwerp, Antwerp, Belgium. |
| Abstrakt: |
In vitro studies suggest that certain probiotic bacterial strains have potential activity against opportunistic infections such as Candida. There are few in vivo trials using probiotics as a single treatment for acute Candida vulvovaginitis (CV). In this open-label, proof-of-concept study, selected Lactobacillus strains were tested in women with acute Candida vaginitis. Twenty women diagnosed with proven, symptomatic CV were instructed to administer a vaginal probiotic gel with L. plantarum YUN-V2.0, L. pentosus YUN-V1.0 and L. rhamnosus YUN-S1.0 for 10 consecutive days. Vaginal rinsing fluid, vaginal culture swab and vaginal smear for fresh wet-mount microscopy were collected before and 7, 14 and 28 days after start of treatment. On average, participating women were 39 years old and had an history of 5 vaginal infections of which 95% was CV. Nine women (45%) completed the study without the need of rescue medication. Women who needed rescue treatment experienced twice as much Candida infections in the past. A negative correlation was found between the clinical composite score and the time to use rescue medication (R 2 = 0.127). Seventy-four per cent of participants found the study gel comfortable to use, and 42% of all women would use the tested gel again for this indication. Forty-five per cent of women were treated successfully for acute CV with a novel vaginal gel containing 3 selected Lactobacillus strains. Patients needing rescue treatment were suffering from more severe and long-standing disease. These results warrant for further testing of this new product, especially of its potential in cases with mild to moderate severity, as an adjuvant to antimycotics or as a preventive measure in women with recurrent vulvovaginal candidosis. |
Full text from SpringerLink